Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Daniell Richard
 2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2018		 3. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]
(Last)
(First)
(Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Exec. VP, European Commercial
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

PETACH TIKVA, L3 4951033		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy)   (1) 12/05/2020 Ordinary Shares (2) 5,255 $ 49.11 D  
Stock Options (right to buy)   (3) 02/23/2021 Ordinary Shares (2) 5,120 $ 50.12 D  
Stock Options (right to buy)   (4) 11/06/2021 Ordinary Shares (2) 11,254 $ 41.72 D  
Stock Options (right to buy)   (5) 02/23/2022 Ordinary Shares (2) 7,204 $ 44.59 D  
Stock Options (right to buy)   (6) 12/12/2022 Ordinary Shares (2) 2,501 $ 38.84 D  
Stock Options (right to buy)   (7) 02/23/2023 Ordinary Shares (2) 5,003 $ 38.08 D  
Stock Options (right to buy)   (8) 03/11/2024 Ordinary Shares (2) 12,502 $ 48.76 D  
Stock Options (right to buy)   (9) 03/11/2025 Ordinary Shares (2) 15,001 $ 60.21 D  
Stock Options (right to buy)   (10) 03/16/2026 Ordinary Shares (2) 27,504 $ 53.5 D  
Stock Options (right to buy)   (11) 09/08/2026 Ordinary Shares (2) 14,571 $ 50.21 D  
Stock Options (right to buy)   (12) 03/03/2027 Ordinary Shares (2) 45,003 $ 34.7 D  
Stock Options (right to buy)   (13) 09/18/2027 Ordinary Shares (2) 15,011 $ 16.99 D  
Restricted Share Units   (14)   (14) Ordinary Shares (2) 1,429 $ (15) D  
Restricted Share Units   (16)   (16) Ordinary Shares (2) 3,891 $ (15) D  
Restricted Share Units   (17)   (17) Ordinary Shares (2) 2,090 $ (15) D  
Restricted Share Units   (18)   (18) Ordinary Shares (2) 8,395 $ (15) D  
Restricted Share Units   (19)   (19) Ordinary Shares (2) 4,977 $ (15) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Daniell Richard
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
5 BASEL STREET
PETACH TIKVA, L3 4951033		       Exec. VP, European Commercial  

Signatures

/s/ Dov Bergwerk, as attorney-in-fact for Richard Daniell 01/02/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Stock options were granted on December 6, 2010, with 1,751 having vested on each of December 6, 2012 and December 6, 2013 and 1,753 having vested on December 6, 2014.
(2) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(3) Stock options were granted on February 24, 2011, with 1,706 having vested on each of February 24, 2013 and February 24, 2014 and 1,708 having vested on February 24, 2015.
(4) Stock options were granted on November 7, 2011, with 3,751 having vested on each of November 7, 2013 and November 7, 2014 and 3,752 having vested on November 7, 2015.
(5) Stock options were granted on February 24, 2012, with 2,401 having vested on each of February 24, 2014 and February 24, 2015 and 2,402 having vested on February 24, 2016.
(6) Stock options were granted on December 13, 2012 and vested on December 13, 2015.
(7) Stock options were granted on February 24, 2013, with 2,501 having vested on February 24, 2015 and 2,502 having vested on February 24, 2016.
(8) Stock options were granted on March 12, 2014, with 4,167 having vested on each of March 12, 2015 and March 12, 2016 and 4,168 having vested on March 12, 2017.
(9) Stock options were granted on March 12, 2015, with 3,750 having vested on each of March 12, 2016 and March 12, 2017, 3,750 vesting on March 12, 2018 and 3,751 vesting on March 12, 2019.
(10) Stock options were granted on March 17, 2016, with 6,876 having vested on March 17, 2017 and 6,876 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020.
(11) Stock options were granted on September 9, 2016, with 3,642 having vested on September 9, 2017, 3,642 vesting on each of September 9, 2018 and September 9, 2019 and 3,645 vesting on September 9, 2020.
(12) Stock options were granted on March 3, 2017, with 11,250 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 11,253 vesting on March 3, 2021.
(13) Stock options were granted on September 18, 2017, with 7,505 vesting on September 18, 2018 and 7,506 vesting on September 18, 2019.
(14) Restricted share units were granted on March 12, 2015, with 714 vesting on March 12, 2018 and 715 vesting on March 12, 2019.
(15) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
(16) Restricted share units were granted on March 17, 2016, with 1,297 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020.
(17) Restricted share units were granted on September 9, 2016, with 696 vesting on each of September 9, 2018 and September 9, 2019 and 698 vesting on September 9, 2020.
(18) Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021.
(19) Restricted share units were granted on September 18, 2017, with 2,488 vesting on September 18, 2018 and 2,489 vesting on September 18, 2019.
 
Remarks:
The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018.

Exhibit List
     Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.